Compass Pathways Stock News

Atai Life Sciences, the Peter Thiel-backed psychedelic start-up, has increased its stake in Compass Pathways.

Atai Life Sciences, the Peter Thiel-backed psychedelic start-up, has increased its stake in Compass Pathways.

The biotech was priced for perfection; its data wasn''t.

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have been assigned an average recommendation of Buy from the eight research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price target among []

The biotech was priced for perfection; its data wasn't.

COMPASS Pathways (NASDAQ:CMPS) had its target price boosted by HC Wainwright from $100.00 to $120.00 in a research report released on Monday morning, Price Targets.com reports. HC Wainwright currently has a buy rating on the stock. Other research analysts have also issued reports about the company. Zacks Investment Research raised COMPASS Pathways from a sell []

During the last session, COMPASS Pathways plc (NASDAQ:CMPS)s traded shares were 0.69 million. At the end of the trading day, the stocks price was $32.04, reflecting an intraday gain of 3.56% or $1.1. The 52-week high for the CMPS share is $61.69, that puts it down -92.54 from that peak though still a striking 10.8% Can COMPASS Pathways plc (NASDAQ: CMPS) Still Be Considered A Loss When Its Down -32.75% YTD? Read More »

Both of these biotech stocks are innovators, but one is more likely to hit it out of the park.

Brokerages expect COMPASS Pathways plc (NASDAQ:CMPS) to announce earnings per share (EPS) of ($0.48) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for COMPASS Pathways earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.47). COMPASS Pathways reported earnings per share of []

COMPASS Pathways plc (NASDAQ:CMPS) was the recipient of a large increase in short interest in October. As of October 29th, there was short interest totalling 1,120,000 shares, an increase of 44.7% from the October 14th total of 774,200 shares. Based on an average trading volume of 548,800 shares, the short-interest ratio is presently 2.0 days. []

Hours after psychedelic leader Compass Pathways (NASDAQ:CMPS) announced Phase IIb results from the largest modern study on a psychedelic substance, the stocks of most psychedelic companies holistical

Zacks Investment Research upgraded shares of COMPASS Pathways (NASDAQ:CMPS) from a sell rating to a hold rating in a research note published on Friday morning, Zacks.com reports. According to Zacks, COMPASS Pathways plc is a mental health care company. It operates principally in New York, USA. COMPASS Pathways plc is headquartered in London, UK. []

Positive clinical trial results for psilocybin as a depression treatment didn't have the effect on the stock price that shareholders wanted.